Med spa EBITDA multiples are the single most-searched number in this industry, and for good reason — they translate directly into what your practice is worth. This is a data-first companion to Med Spa & Medical Aesthetics Valuation: What Actually Drives Value: that guide explains how valuation works and what moves your multiple; this one is the current benchmark table itself, by size band, sourced and dated so you know exactly where the numbers come from.
Sourced from the American Med Spa Association 2026 industry look-back, Scope Research, FOCUS, Breakwater, Sofer, and HealthFMV. Ranges reflect general market data as of this refresh and are not a guarantee of any specific outcome.
There is no single average med spa ebitda multiple — the range depends heavily on size, growth, and infrastructure. Here is the current benchmark table:
| Size Band | Typical Multiple | Basis |
|---|---|---|
| Under $1M EBITDA | ~2.1x–3.9x cash flow | SDE (seller’s discretionary earnings) |
| $1M–$3M EBITDA | ~5x–9x | Adjusted EBITDA |
| Under $4M revenue | ~3x–6x | Adjusted EBITDA |
| $4M–$20M revenue | ~5x–8x | Adjusted EBITDA |
| Over $20M revenue / regional platforms | ~7x–12x | Adjusted EBITDA |
| National, tech-enabled platforms | ~10x–20x | Adjusted EBITDA |
Typical EBITDA margins across the category run 20–35%, and practices with strong recurring membership revenue can add roughly 0.5x–1.0x to their applicable multiple, reflecting the lower risk buyers assign to predictable, subscription-based revenue over one-off transactional revenue.
Whether you search medical aesthetics ebitda multiples, medical spa valuation multiples, aesthetic practice ebitda multiples, or med spa multiples, you’re looking at the same underlying data set — these are simply different phrasings buyers, brokers, and owners use for the same category. The methodology and size-band ranges above apply consistently across all of these terms; medical aesthetics, aesthetic practice, medical spa, and med spa are used interchangeably throughout this industry’s M&A market.
The size-band table above is a useful starting point, but practice structure moves the number within each band. A single-location practice with one owner-provider and a lean team will generally sit toward the lower end of its applicable range, even with strong margins, because the buyer is underwriting significant key-person risk. A multi-location practice with employed medical directors, a documented management layer, and consistent protocols across sites will generally sit toward the higher end, because the buyer is acquiring a more transferable, scalable operation rather than a single person’s book of business.
Franchise or licensed-brand med spas occupy a slightly different category. These practices can command premium multiples due to established brand recognition and operational playbooks, but they also carry franchise fee obligations and territory restrictions that buyers factor into their underwriting — the net effect on multiple varies significantly by brand and franchise agreement terms, and should be evaluated case by case rather than assumed to automatically command a premium.
Deal activity in this category has accelerated meaningfully over the past several years. Publicly tracked med spa transaction counts moved from a handful of deals in 2019 to more than 50 per year by 2023–2024, reflecting the broader wave of private equity interest entering the space. That acceleration in deal volume has generally supported multiple expansion at the platform level, as more capital competed for a limited pool of quality acquisition targets. The 2025 softening in category-wide revenue — driven by market oversaturation in some metros and shifting demand tied to GLP-1 medications — introduced the first meaningful headwind to that multi-year expansion, which is part of why current multiples should be read as a snapshot of today’s conditions rather than a number that only moves in one direction.
Regardless of which size band your practice falls into, the multiple you actually achieve — versus the multiple theoretically available for your category — depends heavily on what you can document and defend in diligence:
Practices that can produce this documentation quickly and completely tend to move through diligence with fewer repricing events than practices where this work has to be assembled reactively once a buyer asks for it. See How to Prepare Your Medical Aesthetics Practice for a Successful Sale for the full preparation checklist.
Owners who search broadly for “healthcare practice multiples” will find ranges that don’t map well onto med spa ebitda multiples specifically. General medical and dental practice multiples are often influenced by factors that don’t apply, or apply differently, here — insurance and payer mix, for example, barely factors into most med spa transactions, since the category is overwhelmingly cash-pay. Conversely, factors that matter enormously to a med spa multiple — injectable-supervision compliance, device financing, membership deferred revenue, CPOM/MSO structure — either don’t exist or matter much less in a typical insurance-based medical practice transaction. This is the core reason a generalist valuation source, or a broker without aesthetics-specific deal experience, tends to produce a less reliable number than one built specifically around this category’s dynamics.
Med spa ebitda multiples data in this article is compiled from multiple industry sources rather than a single provider, because any one data set can be skewed by the size and type of deals that particular source happens to see. The American Med Spa Association publishes an annual State of the Industry Report drawing on member survey data across the category; that is combined here with deal data from M&A advisory and valuation firms including Scope Research, FOCUS, Breakwater, Sofer, and HealthFMV, which see a mix of standalone and platform transactions across different regions and size bands. Cross-referencing multiple sources produces a more reliable directional range than relying on any single firm’s deal flow, which may be concentrated in a particular size band, region, or buyer type.
Because this market moves — deal volume, buyer appetite, and category performance all shift meaningfully year to year — this table is refreshed on an ongoing basis rather than published once and left static. If you’re reading this more than a year after the stated refresh date, treat the directional pattern (owner-dependency and recurring revenue drive multiple; smaller and larger practices sit at different ends of the range) as more durable than the specific numbers, and confirm current figures before relying on them for a transaction.
When an LOI arrives with a specific number attached, the first useful question is which med spa ebitda multiples row it corresponds to — and whether that multiple is being applied to a defensible adjusted EBITDA figure or an inflated one. An offer that looks generous relative to the table above can still be a weak offer once you account for an aggressive add-back schedule, an earnout structure that shifts risk back onto you, or a working capital peg that reduces your actual net proceeds. Conversely, an offer that looks conservative on multiple alone can be strong once favorable structure — cash at close, minimal earnout, clean terms — is factored in. Comparing offers purely on stated multiple, without accounting for structure, is one of the most common ways sellers misjudge which offer is actually best. See Med Spa Deal Structures Explained for how to evaluate structure alongside price.
The size-band ranges above are national benchmarks; realized multiples can vary somewhat by region based on local buyer density and competition among acquirers. States with strict corporate practice of medicine (CPOM) restrictions, such as California, also see a different buyer mix — MSO-structured buyers dominate rather than direct entity buyers — which can affect how a deal is priced and papered even when the underlying multiple is comparable. This is one more reason a single online benchmark, however accurate directionally, should be paired with guidance from an advisor familiar with how these multiples actually play out in your specific state and buyer pool.
The most common mistake owners make with this table is anchoring to the top of the range for their size band without accounting for the value drivers that actually place a specific practice within it. Two practices in the same revenue band can land at opposite ends of their range depending on owner-dependency, recurring revenue mix, provider bench strength, and compliance documentation — all covered in detail in our valuation guide. The table above tells you the range; your own practice’s fundamentals tell you where in that range you actually fall.
“How many times EBITDA is a med spa worth” is really asking which row of the table above applies to a specific practice. As a general pattern: the smaller and more owner-dependent the practice, the lower the multiple, because the buyer is taking on more key-person risk relative to the size of the transaction. As practices scale past roughly $1M in EBITDA and demonstrate the business can run without total owner dependency, multiples climb meaningfully — and above roughly $20M in revenue, where practices start to resemble regional platforms rather than single owner-operated businesses, multiples climb again.
Whether you search medical aesthetics ebitda multiples, aesthetic practice ebitda multiples, or med spa multiples, you’re looking at the same underlying data set — these are simply different phrasings buyers, brokers, and owners use for the same category. The methodology and size-band ranges above apply consistently across all of these terms; medical aesthetics, aesthetic practice, and med spa are used interchangeably throughout this industry’s M&A market.
Margin and multiple are related but distinct. A healthy med spa ebitda margin generally falls in the 20–35% range, though this varies by service mix — practices weighted toward higher-margin injectables and device-based treatments tend to run toward the top of that range, while practices with heavier product/retail components or higher staffing ratios per treatment run lower. Margin matters to your multiple indirectly: a practice with a thin, inconsistent margin signals operational or pricing issues that buyers will price in as risk, independent of the raw EBITDA dollar figure.
Owners sometimes estimate value using a med spa revenue multiple instead of an EBITDA-based approach — multiplying top-line revenue by a rough industry rule of thumb. This can be a useful sanity check, but it’s a much blunter instrument than an EBITDA or SDE-based med spa sale multiple, because two practices with identical revenue can have very different margins, and therefore very different actual earnings for a buyer to underwrite. Serious buyers price on earnings, not revenue; a revenue multiple is, at best, a rough proxy used early in a conversation before real financials are reviewed. For an actual transaction, expect any credible offer to be grounded in med spa transaction multiples applied to adjusted EBITDA or SDE, not simply a percentage of top-line sales.
One of the more important dynamics in this market right now is multiple arbitrage: a standalone practice trading at 5x–9x can be acquired into an existing PE platform at a premium — sometimes toward 10x–14x — because the practice is worth more inside a larger, more efficient structure than it is standing alone. This is a major reason PE platforms have been actively acquiring: they can pay a seller more than a standalone buyer could justify, while still improving their own blended return by adding the practice to a platform that trades, on exit, at the platform’s own higher multiple. Understanding this dynamic is useful context whether you’re evaluating a platform offer or simply trying to understand why offers from different buyer types can vary so widely for the same practice — see Why Private Equity Firms Buy Medical Aesthetics Practices for the full buyer-side thesis.
Med spa valuation multiples 2026 reflect a market that saw its first year-over-year revenue softening across the category in 2025, driven by a mix of oversaturation in some metros and shifting demand patterns tied to GLP-1 medications affecting certain body-contouring and weight-management service lines. An estimated 3–4% of med spas nationally are currently PE-consolidated, with more than 30 active acquisition platforms in the market — named active sponsors include Princeton Medspa Partners, AYA Medical Spa, Shore Capital, VSS Capital, and Eagle Merchant Partners. These med spa valuation benchmarks should be treated as a snapshot of current market conditions, not a permanent baseline; multiples move with capital availability, buyer demand, and category performance, which is why this table is refreshed on an ongoing basis rather than published once and left static.
This table answers “what are practices selling for” — for the full picture of what determines where your specific practice lands within these ranges, see Med Spa & Medical Aesthetics Valuation: What Actually Drives Value, or go straight to the complete process in How to Sell a Med Spa: The Complete Owner’s Guide.